The VYEPTI experience:
Real-world data & peer insights

From the American Headache Society position statement update, 2024

Real-world studies include both prospective and retrospective studies. Although the evidence provided by these studies is not considered to be of the same quality as randomized control trials (RCTs), they are very useful in that they generally confirm the results of the RCTs regarding efficacy, tolerability, and safety, and they do so within a wide variety of international cohorts, often over longer time periods.¹

REVIEW study: exploring patient experience with VYEPTI

This observational, real-world study was designed to assess satisfaction with VYEPTI effectiveness, infusion experience, and clinical impact from both patient and physician perspectives in day-to-day healthcare settings. The results below reflect the personal interpretation of each survey question from 94 patients with chronic migraine who had 6 or more months of treatment with VYEPTI.²

Patients were asked to compare their experience with migraine before and after starting VYEPTI. Survey responses were dependent on patient recall and may have been further impacted by the span of time from diagnosis up through treatment cycles with VYEPTI. Safety data were not collected for the study; any adverse events were collected via standard reporting methods.² Please see VYEPTI safety and tolerability data to learn more. See select study design details and additional study limitations below.

Explore the VYEPTI pivotal trials and 2-year patient-reported outcomes data to see if VYEPTI could be right for your patients.

~70% patients reported increased satisfaction with their ability to plan, be productive, & participate in their daily lives

Patient satisfaction with impact on elements of daily living after starting VYEPTI²*^†

Levels of satisfaction:

Much higher/Higher About the same Lower/Much lower

*Patients (N=94) were asked to rate the following statements about different aspects of their daily life: “After starting VYEPTI, my satisfaction with my…” Choices included: much higher, higher, about the same, lower, and much lower.

†Patients (62%, n=58/94) also reported “higher or much higher” satisfaction with their ability to return to their daily responsibilities faster after a migraine attack. Other options were “about the same” (35%, n=33/94) and “lower or much lower” (3%, n=3/94).

Mean number of good days per month before and after starting VYEPTI^2‡

Before (n=93) After (n=93)

Chart showing that the mean number of “good days” per month increased from 8 before VYEPTI to 18 “good days” per month after starting VYEPTI.

After starting VYEPTI, patients reported >2x the amount of monthly good days.

Of the 74 patients who indicated their migraine experience included brain fog, 86% reported improvement in brain fog

Degree to which brain fog symptoms improved after starting VYEPTI²**

Chart showing that of the 74 patients who reported experiencing brain fog, 14% (n=10) responded that VYEPTI did not improve their brain fog, 23% (n=17) reported a slight improvement, 26% (n=19) reported moderate improvement, 32% (n=24) reported VYEPTI very much improved their brain fog, and 5% (n=4) reported that VYEPTI completely improved their brain fog.

Brain fog was defined as: Feeling confused, having difficulty learning or remembering, or having trouble speaking or reading.

¶Result reflects those who responded: completely, very much, moderately, or slightly.

**Patients (n=93) were asked, “Have you experienced ‘brain fog’?” Patients who responded ‘yes’ (n=74/93) were then asked to, “…rate to what extent your symptoms improved since starting VYEPTI.” Choices included: completely, very much, moderately, slightly, or not at all.

Read full clinical publication

For REVIEW, 3 components comprised the study: a structured patient survey intended to measure their satisfaction with VYEPTI, a retrospective chart review, and a semi-structured healthcare provider interview. Study data reflect patients' experiences with migraine treatment and their migraine symptomatology collected across 4 study sites in the US. Data are survey-based and dependent upon patient recall. Descriptive statistics were used; no conclusions can be drawn.^2,3

To participate, patients must have completed a minimum of 2 consecutive infusion cycles (≥6-month exposure) with 51% of patients having received 5 or more at the time of the survey. Patients were not excluded based on comorbidities.

The structured patient survey underwent linguistic validation to ensure that patients understood the intent of each question.²

Select baseline characteristics

Mean age: 49.2 years (median: 49 years)
Mean time since diagnosis: 15.4 years (median: 12 years)
Current VYEPTI dose: 57% 300 mg | 23% 100 mg | 19% cannot recall/missing/other
100% of respondents had prior preventive treatment: 89% anti-CGRP mAb | 82% OnabotulinumtoxinA | 74% oral preventive | 73% Gepant

Select inclusion criteria

Over 18 years of age
Diagnosis of chronic migraine (per the patient’s chart)
Received ≥2 consecutive VYEPTI infusion cycles
Ability to complete survey in English

Exclusion criteria

Treated with VYEPTI in a clinical trial setting
Enrolled in another clinical trial for migraine

Limitations

Patient data were survey-based, self-reported, and dependent on patient recall
Patient population selected based on treatment with VYEPTI regardless of prescribed dosage, suggesting positive responses and tolerability
No cross-comparisons were conducted among outcome measures for the 100 mg, 200 mg, or 300 mg doses
Gepants were not excluded, and methodology did not support differentiation between preventive and acute use
Inherent selection bias in the study could not be mitigated
Results are descriptive data; no formal statistical analyses were performed

CGRP, calcitonin gene-related peptide; mAb, monoclonal antibody.

VYEPTI from the perspective of your peers

Examining the burden of chronic migraine and a clinical case study

"It’s so important for us to really understand what our patients experience and how we can provide support both emotionally and clinically."

Wade Cooper, DO

Treating chronic migraine, illustrated by a patient case study

"We'll dig deeper into the VYEPTI patient reported outcomes data as reported in the clinical trials."

Peter McAllister, MD FAAN

Voices of VYEPTI

Learn about the personal experience from patients prescribed VYEPTI

Despite being on a preventive and an acute treatment, migraine dictated Chanci’s daily life

Inability to be present with friends and family
Isolated due to light and noise sensitivity
Frequent migraine days as well as daily headaches
Migraine attacks increasing in frequency and severity despite taking preventive medication
Increased use of acute medication without relief

Her neurologist recognized a change was needed and prescribed VYEPTI

REVIEW PATIENT IMPACT DATA

“My migraine attacks made me feel helpless. I needed to do something different. My neurologist and I decided to try VYEPTI.”

Chanci, real VYEPTI patient

Patient results may vary.

of ~1,100 people with migraine surveyed in 2021 were dissatisfied with their ability to control their disease.^4††

††Survey consisted of people diagnosed with migraine disease for ≥2 years and who satisfy at least 1 of the following: ≥8 migraine attacks in the prior month, have been prescribed a preventive migraine treatment, or are either currently taking or have previously taken a preventive migraine treatment.

Hear from more patients who were moved to VYEPTI

Lou, Lealani, and Electra, real VYEPTI patients

“When I would have my migraine attacks, my life was on hold. My experience on VYEPTI has given me the opportunity to do the things I used to do. It’s given me a second chance at life.”

Lou is a former college athlete whose chronic migraine slowed her down. Then her doctor prescribed VYEPTI.

Lou, real VYEPTI patient

“It has caused me to lose jobs...not experience things with my family. I almost missed my own wedding. Before VYEPTI, I could not write things on a calendar and expect to keep them.”

Lealani had a hard time planning anything because chronic migraine kept getting in the way. Then she read about VYEPTI and asked her doctor.

Lealani, real VYEPTI patient

“I've just kind of been living day by day. I told myself, I can't keep living like this. There has to be something that can help me.”

Electra was struggling with chronic migraine and joined the VYEPTI clinical trial. Once it was approved, she started treatment.

Electra, real VYEPTI patient

June, Nicole, and Cynthia, real VYEPTI patients

“My infusion experience has been positive. I go to an infusion center. It’s just 30 minutes. I lay back and relax. They come and check on me and I’m done.”

June is a long-time chronic migraine sufferer whose chronic migraine negatively affected her relationship with her granddaughter. Then she and her doctor decided to try VYEPTI.

June, real VYEPTI patient

“I no longer spend endless time tracking every trigger and medication I am taking, so my time is freed up to do more of the things that I love.”

A passionate patient advocate who struggled to engage with life like she wanted because of chronic migraine, Nicole worked with a doctor to start VYEPTI after several failed treatments.

Nicole, real VYEPTI patient

“I actually love knowing that 100% of the infusion is going into my bloodstream—that VYEPTI is completely going into my body."

Cynthia struggled with chronic migraine with brain fog that got in the way of her pursuing her goals. Then she asked her doctor about VYEPTI, despite her hesitancy about an IV infusion.

Cynthia, real VYEPTI patient

All real VYEPTI patients on this page were compensated for their time. Patient results may vary

The VYEPTI experience: Real-world data & peer insights

Real-world evidence

Hear from your peers

Patient testimonials